Aktuellt
SENASTE
Redeye is discouraged by yesterday’s drastic announcement of a strategic reprioritization and thus pause of its two ongoing phase IIb studies with lead candidate Tesomet due to financial uncertainties. We significantly lower our base case close to yesterday’s closing price and argue that Saniona will have to urgently prove that it has a path forward to regain confidence in the management and stock going forward - before it is too late.
LÄS MER
